INZY
insider transactionsInozyme Pharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·U
Director
$6.3M
1.6M sh · $4.00
-
Other·U
Director
$11.7M
2.9M sh · $4.00
-
Other·D
Director
—
234.2K sh
Own -100%
-
Other·D
Director
—
159.2K sh
Own -100%
-
Other·U
Director
$1.7M
423.9K sh · $4.00
-
Other·D
SVP, CFO & Head of BD
—
38.5K sh
Own -100%
-
Other·D
SVP, CFO & Head of BD
—
180.0K sh
Own -100%
-
Other·D
SVP, CFO & Head of BD
—
135.0K sh
Own -100%
-
Other·D
SVP, CFO & Head of BD
—
145.0K sh
Own -100%
-
Other·U
SVP, CFO & Head of BD
$158.8K
39.7K sh · $4.00
-
Other·D
COO
—
145.0K sh
Own -100%
-
Other·D
COO
—
41.5K sh
Own -100%
-
Other·U
COO
$87.0K
21.7K sh · $4.00
-
Other·D
Director
—
28.4K sh
Own -100%
-
Other·D
Treco Douglas A KEY
CEO & Chairman
—
150.0K sh
Own -100%
-
Other·D
Treco Douglas A KEY
CEO & Chairman
—
87.0K sh
Own -100%
-
Other·D
Treco Douglas A KEY
CEO & Chairman
—
400.0K sh
Own -100%
-
Other·U
Treco Douglas A KEY
CEO & Chairman
$175.4K
43.9K sh · $4.00
-
Grant·A
COO
$10.6K
14.4K sh · $0.74
Own +194%
-
Grant·A
SVP, CFO & Head of BD
$5.0K
6.8K sh · $0.74
Own +21%
-
Grant·A
Treco Douglas A KEY
CEO & Chairman
$2.1K
2.8K sh · $0.74
Own +7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2025 | Hopfner Robert Lorne | Other U | 1.6M | $6.3M |
| Jul 1, 2025 | Hopfner Robert Lorne | Other U | 2.9M | $11.7M |
| Jul 1, 2025 | Bolte Axel | Other D | 234.2K | — |
| Jul 1, 2025 | Bolte Axel | Other D | 159.2K | — |
| Jul 1, 2025 | Bolte Axel | Other U | 423.9K | $1.7M |
| Jul 1, 2025 | Subramanian Sanjay KEY | Other D | 38.5K | — |
| Jul 1, 2025 | Subramanian Sanjay KEY | Other D | 180.0K | — |
| Jul 1, 2025 | Subramanian Sanjay KEY | Other D | 135.0K | — |
| Jul 1, 2025 | Subramanian Sanjay KEY | Other D | 145.0K | — |
| Jul 1, 2025 | Subramanian Sanjay KEY | Other U | 39.7K | $158.8K |
| Jul 1, 2025 | Winton Matthew | Other D | 145.0K | — |
| Jul 1, 2025 | Winton Matthew | Other D | 41.5K | — |
| Jul 1, 2025 | Winton Matthew | Other U | 21.7K | $87.0K |
| Jul 1, 2025 | Sullivan Lynne Marie | Other D | 28.4K | — |
| Jul 1, 2025 | Treco Douglas A KEY | Other D | 150.0K | — |
| Jul 1, 2025 | Treco Douglas A KEY | Other D | 87.0K | — |
| Jul 1, 2025 | Treco Douglas A KEY | Other D | 400.0K | — |
| Jul 1, 2025 | Treco Douglas A KEY | Other U | 43.9K | $175.4K |
| Jun 25, 2025 | Winton Matthew | Grant A | 14.4K | $10.6K |
| Jun 25, 2025 | Subramanian Sanjay KEY | Grant A | 6.8K | $5.0K |
| Jun 25, 2025 | Treco Douglas A KEY | Grant A | 2.8K | $2.1K |
About INZY insider trading
This page tracks insider transactions for Inozyme Pharma, Inc. (INZY) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.